医药板块震荡调整，港股通创新药ETF易方达(159316)逆势获3000万份净申购

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 3.1% [1] - The total value of China’s innovative drug License-out transactions grew from $2.562 billion in 2017 to $140.274 billion by 2025, indicating enhanced international competitiveness [1] - Over 70% of innovative drug companies are expected to achieve positive revenue growth by 2025, marking a transition into a commercialization phase for the industry [1] Group 2 - The current valuation of the pharmaceutical sector is considered attractive, with a recommendation to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1] - The ETF tracking the CSI Biotechnology Theme Index, managed by E Fund, has seen a decline of 0.3% [4] - The ETF tracking the CSI Pharmaceutical and Health Index, also managed by E Fund, has similarly decreased by 0.3% [4]